Interstitial Pneumonitis Fibrosis : Biomedic Labs, LLC.

What is Interstitial Lung Disease

Eat Away Pulmonary Fibrosis Scar Tissue

Pulmonary Fibrosis literally means lung (pulmonary) scarring (fibrosis). The lung scarring occurs in the tissue of the lung called the interstitium, which supports the structures of the lung (air sacs/alveoli). There are an estimated 130-200 related diseases called Interstitial Lung Disease that are similar in characteristics and can result in scarring. Pulmonary Fibrosis causes the lung tissue to thicken and become stiff. Scarring inhibits oxygen from entering the blood stream.

Idiopathic Pulmonary Fibrosis
When the cause of Pulmonary Fibrosis is unknown it is called "idiopathic, " or Idiopathic Pulmonary Fibrosis. IPF is the most common form of Interstitial Lung Disease. Below is a summary of the prevalence of the disease

*The actual incidence is unknown.
*It is estimated that 50,000 new cases are diagnosed annually.
*More than 200,000 people in the United States suffer from this disease.
*There are at least 5,000,000 cases world wide.
*It affects both men and women, with a slightly higher incidence in men.
*The average onset age is 40-70 but the disease can occur at any age

Although uncommon, IPF does occur in children and as young as 3 years of age. Interstitial Lung Disease has been diagnosed in children less than one year of age.

*IPF has no specific geographical distribution; it is found in equal proportions in urban and rural environments. A history of smoking has been associated with an increased risk of Idiopathic Pulmonary Fibrosis.

The disease varies from person to person. For some, the disease progresses slowly and gradually over months or years while for others there is a rapid progression. For others, it may stabilize for a period of time. The course is generally unpredictable.

William Wong N.D., Ph.D.
Member World Sports Medicine Hall of Fame.

Anti Fibrosis

Enzymes eat scar tissue and fibrosis. Fibrosis is scar tissue and most doctors learn in anatomy that it is fibrosis that eventually kills us all. Let me explain. As we age, which starts at 27, we have a diminishing of the body's output of enzymes. This is because we make a finite amount of enzymes in a lifetime and we use up a good deal of them by the time we reach our 40's (Cystic Fibrosis patients who have virtually no enzyme production to speak of, even as children usually don't make it past their 20's before they die of the restriction and shrinkage in the lungs from the formation of fibrosis or scar tissue).

So our body begins to dole out our enzymes with an eyedropper instead of with a tablespoon. Result: the repair mechanism of the body goes off balance and has nothing to reduce the over abundance of fibrin it deposits in nearly everything from simple cuts, to the inside of our internal organs and blood vessels. It is then when most women begin to develop things like fibrocystic breast disease, uterine fibroids, and endometriosis. We all grow arterial sclerotic (meaning scar tissue) plaque, and have fibrin begin to spider web its way inside of our internal organs, reducing their size and function over time. This is why as we age our wounds heal with thicker, less pliable, weaker and very visible scars.

If we replace the lost enzymes, we can control and reduce the amount of scar tissue and fibrosis our bodies have. As physicians in the US are now discovering, even old scar tissue can be "eaten away" from surgical wounds, pulmonary fibrosis, and kidney fibrosis even colloid years after their formation. Medical doctors in Europe and Asia have known this and used orally administered enzymes for such for over 40 years!

"What oxygen is to the lungs, such is hope to the
meaning of life."- Emil Brunner

Attention Pulmonary Fibrosis patients SERRACOR-NK the origanal SEBkinase blend is being used by people suffering from: Pulmonary Fibrosis, Emphysema, COPD, and Scarring of the Lungs

SERRACOR-NK can help with Pulmonary Fibrosis by:

Act as cellular detoxifiers to remove toxins in lung cells.
Boosting your bodies natural immune system response.
Dissolve fibrin and scar tissues in the lungs.
Improve lung function and lung flexibility.
Improve breathing and reduce coughing

Serracor-NK is formulated specifically to dissolve Fibrin (scar tissue) through out the body and in the blood stream. Serracor-NK accomplishes this with its two main active ingredients serrapeptase and nattokinase. These two systemic enzymes dissolve fibrin by attaching them selves to the fibrin by a lock and key type action that releases the proteolytic based enzymes of fibrin. When this sequence takes place the fibrin is broken down into enzyme form and then released from the body through sweat, urine and feces. When the build up of fibrin in the lung area starts to dissolve your body immune system will then be able to reach the lungs and begin the healing process. Since a high percentage of people suffering from Pulmonary Fibrosis have developed this condition over many years, the amount of time to be on Serracor-NK varies from person to person. It is strongly suggested that users of Serracor-NK follow the Pulmonary Fibrosis dosage chart and can expect to be on this product from a period of 4-12 months. We have received a strong response from our customers stating that within the first 30 days they have noticed increased airflow and better capability breathing. From the 30-90 day range Serracor-NK users report a significant improvement in breathing, reduction of coughing and mucus, and in some patients the discontinued use of assisted breathing machines. We at Biomedic Labs have seen first hand the miraculous benefits of Serracor-NK for Pulmonary Fibrosis. We have also formulated a product package with Serracor-NK to help with increasing the fibrin breakdown (Serra RX80) and to dissolve and discard mucus in the lung area (Clear lungs). If you have mucus build up Clear Lungs will help with 99% of the mucus in the lungs along with the bacteria that mucus causes. Please read our dosage chart below to see how to help yourself with Serracor-NK.

"We have had about a 95% success rate in people using these products for this condition so please stay encouraged and don't give up despite what you've been told by your physician." -CEO Of Biomedic Labs

The heart normally beats between 60 and 100 times per minute, with many normal variations. For example, athletes at rest have slower heart rates than most people. The normal delay between the contraction of the atria and of the ventricles is 0.12 to 0.20 seconds. Pulmonary fibrosis causes an inflammation and scarring of the air sacs called alveoli, in the lungs. This reduces the ability of the lungs to transfer oxygen. The resulting lack of oxygen in the blood (hypoxemia) may cause increases in the pressure inside the blood vessels of the lungs, a situation known as pulmonary hypertension. The high blood pressure in the lungs then puts a strain on the right ventricle, the lower right side of the heart, which pumps the oxygen-poor blood into the lungs.

In my opinion the situation may be getting worse. Vitalzym may have slowed the condition, but increased heart function may be an indication that the heart is having to work harder to transfer blood and oxygen throughout the body. Serracor unlike Vitalzym lessens the viscosity of blood by carrying the active enzyme Nattokinase. Nattokinase reduces the blood viscosity and cleans the blood reducing stress on the heart. In addition Nattokinase is one of the best enzymes to remove scar tissue. Serrapeptase is also a very good scar tissue removing enzyme. Nattokinase and Serrapeptase work independently in two distinct ways to remove scar tissue from the body. This synergistic effect coupled with the fact the Vitalzym is not nearly as concentrated as Serracor-NK conveys a clear choice for fibrosis patients. Vitalzym will work in less extreme cases but requires many times the dosage to get the potency of just one bottle of Serracor-NK.

Within 6 weeks, patients should notice improvement of their symptoms including shortness of breath and coughing with phlegm. After a 3-6 month treatment, patients should have significant improvement in their lung structure. We recommend that patients take a chest x-ray before and after the treatment and compare the diagnostic results to monitor their progress.